Neurocrine Biosciences, Inc. - Common Stock (NBIX)
130.90
-1.58 (-1.19%)
NASDAQ · Last Trade: Apr 7th, 4:20 PM EDT
Detailed Quote
Previous Close
132.48
Open
133.35
Bid
130.90
Ask
137.72
Day's Range
128.99 - 134.20
52 Week Range
84.23 - 160.18
Volume
1,771,789
Market Cap
13.10B
PE Ratio (TTM)
28.09
EPS (TTM)
4.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
998,928
Chart
About Neurocrine Biosciences, Inc. - Common Stock (NBIX)
Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology. Read More
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive agreement to acquire Celeno Therapeutics (NASDAQ: SLNO). The all-cash transaction, valued at approximately $2.9 billion, underscores a strategic push
Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can transition from a single-product success story to a diversified powerhouse. Known primarily for its blockbuster tardive dyskinesia treatment, Ingrezza, Neurocrine is currently at a [...]
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most significant mid-cap success stories of the decade. Soleno Therapeutics (NASDAQ: SLNO) has transitioned from a struggling diagnostics firm to a commercial powerhouse, culminating in [...]
BALA CYNWYD, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has entered into a definitive agreement to acquire the company. The all-cash transaction, valued at approximately $2.9 billion, represents a significant premium
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq: XENE). Long a favorite of biotech specialists for its deep expertise in ion-channel biology, Xenon has officially transitioned from a "high-potential" R&D firm to a "pre-commercial" titan following [...]
